Mylan (MYL) Launches Generic Epivir Tabs in Italy, the U.K. (GSK)

Article Stock Quotes (2) Comments (0)

Mylan Inc. (Nasdaq: MYL) says its UK and Italy-based subsidiaries have launched Lamivudine Film Coated Tablets, 150 mg and 300 mg. This product is the generic version of GlaxoSmithKline's (NYSE: GSK) Epivir Tablets, indicated as part of antiretroviral (ARV) combination therapy for the treatment of HIV-infected adults and children. This is the first generic HIV treatment to be available from Mylan in Europe.

Mylan CEO Heather Bresch commented: "As one of the world's leading providers of affordable ARVs, Mylan has a long history of contributing to the fight against HIV/AIDS across the developing world. We are excited that we can now bring our passion and experience in this important area to the European markets with the launch of Lamivudine, further delivering on our commitment to providing high quality and affordable medicines to patients around the world."

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• EMA Approves MAA for Gilead's (GILD) Sofosbuvir
• Regeneron (REGN) and Genentech Strike Deal on Worldwide EYLEA Sales
• Pfizer (PFE) Discontinues Phase 3 Study of Inotuzumab Ozogamicin

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?